Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eisai Steps Well ‘Beyond The Pill’ In New Japan Care Service

Executive Summary

Japanese major Eisai is working with a communications company for a new online system in Japan that will more closely link chronic disease patients and medical care providers, with a number of expected benefits including treatment compliance that could potentially help stem sales declines for two mainstay products.

You may also be interested in...



Eisai's New Venture Fund Looks To ‘Excavate’ Innovation

Japanese pharma firm’s new venture capital fund aims to support and gain access to external innovation both at home and in the US, while a new alliance with a Japanese tech services firm will pursue opportunities in digital health and dementia.

Japan Pharma Climbing Aboard Digital Health Train, But Not Up To Speed?

The still somewhat loosely defined concept of 'digital health' continues to take concrete forms through recent deals in Japan, where major pharma firms are building initiatives related mainly to patient well-being.

Astellas Dips Into Digital Health Via New Venture

New venture DigiTx will give Astellas a leg up in its quest to access novel digital health technologies, in a move unveiled as the Japanese firm reported continued strong growth for top product Xtandi.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC096880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel